This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Insider Trading Alert - DVA, ACN And BIIB Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, April 2, 2014, 123 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $278.57 to $71,423,275.14.

Highlighted Stocks Traded by Insiders:

DaVita HealthCare Partners (DVA) - FREE Research Report

Mildenberger Laura who is Chief People Officer at DaVita HealthCare Partners sold 598 shares at $69.22 on April 2, 2014. Following this transaction, the Chief People Officer owned 5,438 shares meaning that the stake was reduced by 9.91% with the 598-share transaction.

Staffieri Michael David who is COO, Kidney Care at DaVita HealthCare Partners sold 2,867 shares at $69.15 on April 2, 2014. Following this transaction, the COO, Kidney Care owned 2,633 shares meaning that the stake was reduced by 52.13% with the 2,867-share transaction.

The shares most recently traded at $69.01, down $0.14, or 0.2% since the insider transaction. Historical insider transactions for DaVita HealthCare Partners go as follows:

  • 4-Week # shares sold: 16,489
  • 12-Week # shares sold: 26,489
  • 24-Week # shares sold: 26,489

The average volume for DaVita HealthCare Partners has been 1.5 million shares per day over the past 30 days. DaVita HealthCare Partners has a market cap of $14.8 billion and is part of the health care sector and health services industry. Shares are up 9.01% year-to-date as of the close of trading on Wednesday.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease. It operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals. The company has a P/E ratio of 24.0. Currently there are 9 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DVA - FREE

TheStreet Quant Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in stock price during the past year, growth in earnings per share, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full DaVita HealthCare Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Submit an article to us!
DOW 17,089.41 +2.78 0.02%
S&P 500 1,988.49 +1.48 0.07%
NASDAQ 4,469.5740 -4.1230 -0.09%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs